What is CHD Bioscience?
CHD Bioscience is a biotechnology firm dedicated to combating hospital-acquired infections by developing advanced disinfectants. The company's core mission involves discovering, developing, and commercializing products aimed at preventing and treating infectious diseases in both human and animal populations across industrialized and developing nations. Based in Fort Collins, Colorado, CHD Bioscience is strategically positioned to address critical global health challenges through innovative scientific solutions.
How much funding has CHD Bioscience raised?
CHD Bioscience has raised a total of $10.9M across 4 funding rounds:
Private Equity
$3.2M
Private Equity
$1.7M
Private Equity
$3.3M
Private Equity
$2.7M
Private Equity (2014): $3.2M, investors not publicly disclosed
Private Equity (2015): $1.7M, investors not publicly disclosed
Private Equity (2016): $3.3M, investors not publicly disclosed
Private Equity (2017): $2.7M, investors not publicly disclosed
What's next for CHD Bioscience?
With substantial enterprise-level backing, CHD Bioscience is poised for accelerated growth and expanded market penetration. The company's focus on critical pathogen control suggests a strategic direction towards scaling its research and development capabilities, potentially leading to new product lines or enhanced efficacy of existing ones. Future endeavors will likely involve further clinical validation, regulatory approvals, and broader distribution networks to fulfill its mission of reducing infectious disease burdens worldwide. This significant capital infusion will be instrumental in achieving these ambitious goals.
See full CHD Bioscience company page
